SpaceX's $123 Billion Lockup Cliff Meets a Reviving IPO Pipeline

The largest IPO in US history is about to face its first real structural test — and it arrives the same week the broader issuance market is finding its footing.

SpaceX (SPCX) went public on June 12, 2026, raising $75 billion at $135 per share in a deal that commanded a roughly $1.7 trillion market cap at listing.^[1] Only about 555.6 million shares — roughly 5% of the company — were sold in the offering, the thinnest float for a megadeal in modern memory.^[2] That thin float is about to get a lot wider.

On August 4, SpaceX reports its first-ever quarterly earnings. Two days later, on August 6, the first major lockup expiration releases approximately 911.5 million shares — roughly 20% of locked-up stock — into the tradable float.^[3] A second tranche of 455.8 million shares unlocks around August 20.^[4] Further expirations continue through September and beyond, ultimately making more than 6.4 billion shares eligible to trade over the next year — against the 629 million sold at IPO.^[4]

The Numbers on the Cliff

At the July 24 close of $115.07, SPCX has already fallen roughly 15% below its $135 IPO price and about 43% from its first-week peak above $201.^[5] Pre-market on July 27 shows the slide continuing, with shares trading at $112.98 as of 08:45 ET — down another 1.8% from the close.^[5]

The scale of the unlock dwarfs the IPO itself. At current prices, the August 6 tranche alone represents roughly $105 billion in newly tradable shares. The August 20 tranche adds another ~$53 billion. Together, the two August expirations put roughly $158 billion of stock into the float — against the $75 billion raised in the original offering.^[3]

Matthew Kennedy, senior strategist at Renaissance Capital, frames the structural anomaly plainly: “SpaceX floated about 5% of its shares, so there are a lot more shares locked up here than a typical IPO. It makes sense, given the size of the company, but it’s a large technical overhang nonetheless.”^[4] The average IPO typically sells about 20% of shares to the public.^[4]

Kennedy adds that SpaceX has “the longest series of lock-up releases we’ve ever seen”^[4] — a staggered schedule that stretches through the first anniversary of the IPO in June 2027, when Elon Musk’s own stake becomes eligible (though he has said he does not plan to sell).^[4]

Morningstar analyst Nicolas Owens estimates that “most of the available shares will come to market, because the existing sellers have low cost basis and long holding periods.”^[4] He also notes that “it’s conceivable that a good deal of the recent slump in SpaceX stock is precisely in anticipation of the dilution from the lockup.”^[4]

The Index Fund Absorption Mechanism

One structural counterweight exists: as the float expands, SPCX’s weighting in cap-weighted index funds increases. Morningstar’s Zachary Evens points to the Invesco QQQ Trust (QQQ), which held roughly 39.7 million SPCX shares worth $4.57 billion at a 0.98% portfolio weight on July 22.^[4] If the float-adjusted market cap triples by the end of September — which Morningstar says could happen — SPCX would be treated as a $675 billion company in the Nasdaq index, placing it between Walmart and Intel in QQQ’s portfolio.^[4]

But Owens is skeptical that passive demand will be enough: “Unless something changes the fundamental story or sentiment — like for the better — the supply from these lockups will outweigh demand even from index funds.”^[4]

I’d put the probability of meaningful net selling pressure through September at roughly 70/30. The 30% case for absorption without material price decline requires three things to be true simultaneously: strong Q2 earnings on August 4 that reset the narrative, a benign broader market that supports risk appetite, and index fund rebalancing that mechanically absorbs the incremental supply. Each is plausible. All three together is a lot to ask.

The IPO Pipeline Is Filling — But Unevenly

The lockup cliff doesn’t arrive in isolation. The US IPO market staged a sharp Q2 recovery, with 48 deals pricing in the quarter — led by SpaceX’s record-setting raise but also including nine other IPOs that raised $1 billion or more.^[1] The Renaissance IPO Index was up 16.7% year-to-date as of July 23, outpacing the S&P 500’s 8.9% gain over the same period.^[6]

Yet 87 IPOs have priced year-to-date, a 26.9% decline from the prior year,^[1] and Forge Global’s July pipeline outlook notes that “VC-backed IPO performance since Q1 2025 has been uneven” — a “more nuanced market rather than a simple ‘open’ or ‘closed’ IPO window.”^[7] A reported 800-company backlog sits in the pipeline, but Forge notes that companies keep deferring rather than canceling, waiting for better windows.^[7]

Jersey Mike’s: The Consumer Brand Test

Jersey Mike’s Subs launched its IPO roadshow on July 20, offering 43,478,261 Class A shares at $21–$25.^[8] At the $23 midpoint, the deal grosses roughly $1.0 billion^[8] and implies a market cap near $7.3–7.9 billion on roughly 317.6 million total shares.^[9] Blackstone acquired the chain last year at an $8 billion valuation;^[9] the IPO structure includes selling stockholders receiving proceeds, with the company targeting roughly $301 million in primary proceeds to pay down debt.^[9] The 3,300-unit, ~99% franchised sandwich chain trades on NYSE under the ticker JMKE.^[9]

The roadshow’s reception will be one signal of whether the market’s appetite extends beyond AI infrastructure and defense — categories that have dominated 2026 issuance — into consumer-franchise equities. Renaissance Capital’s calendar shows JMKE as the marquee deal for the week of July 27.^[10]

Biotech and Defense: New Filings Keep Coming

The week of July 20 saw Scribe Therapeutics (SCTX) price its $129 million IPO at the high end, popping 44% on the first day — a CRISPR-based cardiovascular play with initial data expected in H1 2027.^[6] Defense tech firm Lyntris (LYNX) filed for an estimated $300 million offering^[6] — the kind of name that fits the 2026 issuance pattern of AI-tailwind and defense-adjacent companies. Gravitics (GVTX), a space structures developer, filed for a $125 million deal.^[6] Four SPACs also priced, including a $325 million vehicle led by venture capitalist David York.^[6]

But not every deal worked. The prior week, data center operator Csquare (CSQR) priced below range and fell 2%, while nuclear fuel maker Standard Nuclear (STDN) slashed its offering by more than half and then plunged 18%^[1] — both stumbling into a broader AI infrastructure selloff.^[1]

Follow-On Offerings: The Dilutive Back Channel

While IPOs grab headlines, the follow-on market is quietly running hot. Three notable dilutive raises priced in July:

All three are dilutive primary offerings — companies issuing new shares to raise cash, not selling stockholders cashing out. Erasca upsized its deal, suggesting decent demand at the clearing price. But the clustering of biotech follow-ons in a single month signals that the sector’s funding window is open now, and companies are taking it before conditions shift.

Buybacks: The Other Side of the Liquidity Equation

While the IPO and follow-on markets add supply, buybacks absorb it — and several sizable programs are actively running:

• RELX PLC announced a non-discretionary buyback program running July 23–September 4, 2026, spending £150 million, following the successful completion of a £100 million program on July 21.^[12]
• Flagstar Bank (FLG) authorized a $250 million share repurchase program on July 24, citing “strong capital position.”^[12]
• Banco Santander continued active buyback executions between July 16–22 under its board-approved program.^[12]
• Pepco Group launched a tender buyback of up to €400 million as a one-time capital return.^[12]

These programs provide a modest demand sink, but their combined scale is a fraction of what the SPCX lockup alone will release. The buyback market is steady-state support, not a structural offset for a one-time supply shock.

What to Watch Next

1. August 4 — SpaceX Q2 earnings (after close): The first public financials. Revenue trajectory, Starlink economics, and any guidance commentary will set the tone heading into the lockup expiration. If results disappoint, the selling pressure on August 6 could be acute.

2. August 6 — First lockup expiration (~911.5M shares): The first real test of whether the float can absorb supply. Watch for volume spikes in the first 30 minutes of trading and whether the bid side holds. The 911.5 million share figure represents 20% of locked stock per the S-1.^[3]

3. August 20 — Second lockup tranche (~455.8M shares): A second, smaller wave.^[4] By this point the market will have two weeks of post-unlock trading data to price in. If the August 6 unlock was absorbed cleanly, August 20 may be a non-event. If not, it compounds.

4. Jersey Mike’s (JMKE) pricing and first-day performance: Expected to price during the week of July 27.^[10] The consumer-franchise IPO’s reception tells us whether appetite extends beyond the AI/defense trade. A weak first day could cool the consumer-IPO pipeline.

5. September index rebalancing: As SPCX’s float expands, index providers review weights quarterly. If the float-adjusted market cap triples by end of September, as Morningstar’s Evens projects,^[4] passive funds will need to buy more — a mechanical demand source, but one that lags the supply by weeks.

6. Follow-on offering pace through August: If the biotech follow-on window stays open — watch for new filings and pricings — it signals that institutional demand for equity issuance remains intact even as the SPCX unlock dominates headlines.

The honest forecast: I’d put the probability of significant SPCX price pressure through the August 6–20 window at roughly 70%. The 30% case for clean absorption requires strong earnings, stable broader markets, and index-fund mechanics working faster than they typically do. The staggered structure helps — releasing supply in tranches rather than one flood — but the sheer volume, against a thin float and a stock already 15% below its IPO price, makes this the most structurally loaded post-IPO window in market history. The rest of the issuance calendar — Jersey Mike’s, the defense-tech pipeline, the biotech follow-ons — will compete for the same liquidity at the same time.